Robert Frantz, MD, FACC, Director, Pulmonary Hypertension Clinic, Mayo Clinic, says that the issue of cost is an important factor in treating patients with pulmonary arterial hypertension.
Robert Frantz, MD, FACC, Director, Pulmonary Hypertension Clinic, Mayo Clinic, says that the issue of cost is an important factor in treating patients with pulmonary arterial hypertension. Dr Frantz also says that patients with pulmonary arterial hypertension who contract a blood stream infection will most likely require costly hospitalization and run the risk of other health issues.
This video was taken on Sunday, October 21 at the CHEST 2012 conference in Atlanta, GA.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More